...
首页> 外文期刊>Circulation journal >Mechanical Dyssynchrony Is Not Everything of Substrate but Is Essential for Cardiac Resynchronization Therapy – Is Assessment of Mechanical Dyssynchrony Necessary in Determining CRT Indication? (Pro) –
【24h】

Mechanical Dyssynchrony Is Not Everything of Substrate but Is Essential for Cardiac Resynchronization Therapy – Is Assessment of Mechanical Dyssynchrony Necessary in Determining CRT Indication? (Pro) –

机译:机械不同步不是基质的全部,而是心脏再同步治疗所必需的-是否需要评估机械不同步才能确定CRT适应症? (专业版)–

获取原文
           

摘要

Cardiac resynchronization therapy (CRT) improves heart failure symptoms, cardiac function and long-term prognosis. As a result, it has been established as a treatment for refractory heart failure by using a specialized pacemaker to restore coordinated ventricular contractions with pacing. Despite being an invasive treatment, however, the above effects are not observed in 30-45% of patients selected based on the standard criteria that includes New York Heart Association class III or IV heart failure, left ventricular ejection fraction ≤35%, and QRS duration ≥120 or 130ms. From the fact that quantifiable resynchronization was associated with hemodynamic and clinical improvements, it should follow that mechanical dyssynchrony is a critical substrate for the benefits from CRT. The PROSPECT study unexpectedly demonstrated limitations of echocardiographic parameters using M-mode, pulsed-wave Doppler, and tissue Doppler imaging for accurately and reproducibly predicting response to CRT. However, advances in speckle tracking strain and real-time 3-D echocardiography have furthered the development of more sophisticated indices of dyssynchrony. Stress echocardiography might be useful for the detection of latent mechanical dyssynchrony in failing hearts. Because the substrate for CRT efficacy is multifactorial, a discriminant score that includes various clinical parameters and echocardiographic indices of mechanical dyssynchrony is needed to improve patient selection for CRT. ( Circ J 2011; 75: 457-464)
机译:心脏再同步治疗(CRT)可改善心力衰竭症状,心脏功能和长期预后。结果,通过使用专用的起搏器通过起搏恢复协调的心室收缩,已将其确立为难治性心力衰竭的治疗方法。尽管是侵入性治疗,但根据标准标准(包括纽约心脏协会III级或IV级心力衰竭,左心室射血分数≤35%和QRS)选择的患者中,没有观察到上述效果的30-45%持续时间≥120或130ms。从可量化的再同步与血液动力学和临床改善相关的事实出发,应该得出结论,机械不同步是CRT获益的关键因素。 PROSPECT研究出乎意料地证明了使用M型,脉冲波多普勒和组织多普勒成像技术准确,可重复地预测对CRT的反应时超声心动图参数的局限性。但是,斑点跟踪应变和实时3-D超声心动图技术的进步进一步促进了不同步性更复杂指标的发展。应力超声心动图对于检测心脏衰竭中潜在的机械不同步可能有用。由于CRT疗效的底物是多因素的,因此需要包括各种临床参数和机械不同步的超声心动图指标的判别评分,以改善CRT的患者选择。 (Circ J 2011; 75:457-464)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号